Cochrane
Library

Cochrane Database of Systematic Reviews

Anticonvulsants for fibromyalgia (Review)

Üçeyler N, Sommer C, Walitt B, Häuser W

Üçeyler N, Sommer C, Walitt B, Häuser W.

Anticonvulsants for fibromyalgia.

Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD010782.

DOI: 10.1002/14651858.CD010782.pub2.

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
REASON FOR WITHDRAWAL	1
WHAT'S NEW	1
HISTORY	2

[Intervention Review]

Anticonvulsants for fibromyalgia

Nurcan Üçeyler¹, Claudia Sommer¹, Brian Walitt^{2,3}, Winfried Häuser^{4,5}

¹Department of Neurology, University of Würzburg, Würzburg, Germany. ²National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD, USA. ³National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA. ⁴Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, München, Germany. ⁵Internal Medicine 1, Klinikum Saarbrücken, Saarbrücken, Germany

Contact address: Winfried Häuser, Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Langerstr. 3, München, D-81675, Germany. whaeuser@klinikum-saarbruecken.de.

Editorial group: Cochrane Pain, Palliative and Supportive Care Group.

Publication status and date: Withdrawn from publication for reasons stated in the review, published in Issue 10, 2017.

Citation: Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. *Cochrane Database of Systematic Reviews* 2017, Issue 10. Art. No.: CD010782. DOI: 10.1002/14651858.CD010782.pub2.

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

The editorial group responsible for this previously published document have withdrawn it from publication.

REASON FOR WITHDRAWAL

In 2016, this review was passed from the Cochrane Musculoskeletal Review Group to the Pain, Palliative and Supportive Care (PaPaS) Review Group, due to the scope.

At October 2017, this review has been withdrawn. An update was in progress and was assessed by the Cochrane Funding Arbiter panel, who advised the following:

“Referral ref#239. The Funding Arbiters and Panel received all the information provided in your emails...The problem in this case is ... that fact that the lead author, Dr Nurcan Üçeyler, has received financial support in the last 3 years from commercial sponsors or sources who have a real or potential financial interest in the findings of the review. The Lead Author of a review cannot have any conflicts whatsoever... The original version of the review was not compliant with the policy and neither is this update. Therefore the Funding Panel has determined that the update cannot be published and that the original review should be withdrawn.”

WHAT'S NEW

Last assessed as up-to-date: 30 August 2013.

Date	Event	Description
9 October 2017	Amended	This review has been withdrawn. See Published notes .

HISTORY

Review first published: Issue 10, 2013

Date	Event	Description
23 October 2012	Amended	<p>The protocol 'Antidepressants and centrally active agents for fibromyalgia syndrome' published in 2006 (Nishishinya 2006) has been split into several systematic reviews that will be/have been published as:</p> <ul style="list-style-type: none"> - Anticonvulsants for fibromyalgia - Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome - Non-steroidal anti-inflammatory drugs (NSAIDs), analgesics and opioid agents for fibromyalgia - Sedatives and hypnotic agents for fibromyalgia - Selective serotonin reuptake inhibitors (SSRIs) for fibromyalgia - Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome - Tricyclic agents for fibromyalgia